Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.

Baruah, Manash Pratim; Makkar, B M; Ghatnatti, Vikrant B; Mandal, Kaushik

Baruah, Manash Pratim; Makkar, B M; Ghatnatti, Vikrant B; Mandal, Kaushik.

Afiliación

Baruah MP; Department of Endocrinology, Excel Centre, Guwahati, Assam, India.
Makkar BM; Dr. Makkar's Diabetes and Obesity Centre, New Delhi, India.
Ghatnatti VB; Department of Endocrinology, Kles Dr. Prabhakar Kore Hospital and MRC, Belgaum, Karnataka, India.
Mandal K; Department of Medical Affairs, AstraZeneca Pharma India Limited, Bengaluru, Karnataka, India.

Indian J Endocrinol Metab ; 23(1): 140-149, 2019.

Article en En | MEDLINE | ID: mdl-31016169

Palabras clave

Efficacy; Type 2 diabetes mellitus; hyperglycemia; safety; sodium glucose co-transporter Type 2 inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Indian J Endocrinol Metab Año: 2019 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google